PECAM1 and neoplasm: Fig 5, representing the tumor areas co-stained with PAS and CD31, shows that the apatinib-treated groups have significantly lower PAS-positive areas than the control group with a dose-dependent manner, indicting that apatinib can not only inhibit angiogenesis but also decrease the formation of VM in the melanoma cancer xenografts.